written on 18.06.2014

Lilly/Boehringer's refiled empagliflozin could launch in August


They say the product should gain approval to treat type 2 diabetes on 15 August, based on a two-month Class 1 resubmission (which would give a PDUFA date of 17 August, a Sunday, meaning approval would be likely on the Friday before).